Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$5.83
>-$0.01(-0.49%)
At close: 4:00 PM EST
$5.83
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$3.76 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$41.77M
Enterprise Value$13.32M
Total Cash (Recent Filing)$31.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Aug 17, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding8,611,361
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.11K
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$23.00Price Target Upside294.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Resolved Endoxifen Patent DisputesThe settlement materially reduces IP uncertainty around Z-endoxifen, preserving enforceable patents and defined field allocations. That strengthens long-term competitive protection for lead assets, de-risks licensing/partnership talks and supports strategic development plans over the coming quarters.
Debt-free Balance SheetOperating without debt lowers fixed financial obligations, providing flexibility for a clinical-stage biotech to allocate capital to R&D. This durable advantage reduces bankruptcy risk, preserves optionality for financing choices, and helps manage runway despite negative cash flow.
Shareholder Approvals And Governance ContinuityStrong shareholder approvals and board continuity signal governance stability and management alignment. Authorization of a reverse split and auditor ratification provide durable capital-structure and oversight tools, helping the company manage listing risks and investor confidence while pursuing clinical milestones.
Bears Say
Zero Revenue / No CommercializationAs a clinical-stage company with no product revenue, Atossa depends entirely on external financing and milestone/partner payments to fund operations. This structural absence of commercial cash flow extends time to profitability and increases the risk of dilution or disrupted programs if capital access tightens.
Widening Losses And Accelerating Cash BurnRising operating losses and increasingly negative free cash flow materially raise funding needs and shorten runway absent new financing. Persistent burn pressures capital allocation, risks program delays, and makes sustained R&D execution contingent on continued access to equity or partner capital over the medium term.
Declining Equity And Asset BaseA shrinking equity and asset base erodes the company’s financial buffer to absorb continued losses, reduces capital efficiency, and heightens dependence on external funding. Over time this weakens negotiating leverage with partners and increases vulnerability to dilution from future financings.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $3.76 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $41.77M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 72 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 08, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.99 by -$0.12.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -1.08.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 8,611,361 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.99. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (294.51% Upside)
$23.00 (294.51% Upside)
Hedge Fund Trend
Decreased
By 14.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.34%
12-Months-Change
Fundamentals
Return on Equity
-84.91%
Trailing 12-Months
Asset Growth
-46.37%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$23.00
▲(294.51% Upside)
Technical Analysis
Ownership Overview
2.51% Insiders
29.51% Mutual Funds
<0.01% Other Institutional Investors
63.82% Public Companies and
Individual Investors